Derwent London PLC (DLN)
London Exchange · UK · prices in GBX · close of 20 Oct 2026
Key indicators
| Last close | GBX 1,834.00 |
|---|---|
| 52-week range | 1,404.50 – 2,167.02 |
| Return, 1 month / 3 months | −0.5% / −8.9% |
| Return, 1 year / 3 years | +7.2% / +13.9% |
| Trend | Above 200-day, below 50-day |
| RSI (14) | 50 |
| Volatility (1 year) | 24.7% |
| Worst drawdown (1 year) | -22.7% |
| Average daily value traded | 564.43M GBX |
| Dividend yield | 0.0% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Derwent London is a property company based in London that owns, manages and develops office buildings and mixed-use space, mainly in the West End and the City fringe. Its customers are businesses that lease office and commercial space, and the company also carries out refurbishment and redevelopment of its buildings. The portfolio includes offices and some retail and residential elements, with a focus on central London locations.
The shares are listed on the London Exchange in UK under the code DLN, and the price on this page is in pence sterling (GBX). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Derwent London PLC (DLN) trades on the London Exchange in UK. It last closed at GBX 1,834.00 on 20 October 2026.
Its price-based Market X-Ray is 62 out of 100 (a fair price profile), ranking 1,142 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 7.2% and over the last three months it fell 8.9%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 59 · Fair | Mixed trend against its averages. | |
| Above 200-day average | 1.7% | ||
| From 52-week high | -13.4% | ||
| Momentum | 49 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -8.9% | ||
| 6-month return | 7.4% | ||
| 12-month return, skipping the last month | 7.7% | ||
| Stability (higher is calmer) | 71 · Strong | Calmer than most: low volatility and shallow drawdowns. | |
| Volatility, 1 year (lower is calmer) | 24.7% | ||
| Worst drawdown, 1 year (smaller is calmer) | -22.7% | ||
| Liquidity | 96 · Strong | Trades actively. | |
| Average daily value traded | 564.43M GBX | ||
| Zero-volume days | 0.0% | ||
| Income | 31 · Weak | Dividend is small or irregular. | |
| Dividend yield | 0.0% | ||
| Years with dividends | 5 |
Strengths
- Stability (higher is calmer): Calmer than most: low volatility and shallow drawdowns.
- Liquidity: Trades actively.
Weak spots
- Momentum: Lagging most stocks on this exchange.
- Income: Dividend is small or irregular.
Returns
| 1 week | +1.1% |
|---|---|
| 1 month | −0.5% |
| 3 months | −8.9% |
| 6 months | +7.4% |
| 1 year | +7.2% |
| 3 years | +13.9% |
| 5 years | −34.2% |
Signals
| 50-day / 200-day average | 1,892.51 / 1,804.04 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | Yes |
| Average daily range (ATR) | 48.66 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 3 Sep 2026 | GBP 0.2600 |
| 23 Apr 2026 | GBP 0.5600 |
| 4 Sep 2025 | GBP 0.2550 |
| 24 Apr 2025 | GBP 0.5550 |
| 5 Sep 2024 | GBP 0.2500 |
| 25 Apr 2024 | GBP 0.5500 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.